GlassScriptPhysician profile
Deepthi Kodali
NPI 1750738860
$5,996.02
in general payments reported to CMS, 2019-2025
46 companies · $2,828 in 2025
The $2,828 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $780 · 2024: $2,387 · 2025: $2,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199 · Long Term Medical Supply Or Device Loan: $1,696 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.10 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Education | $100.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,089.94 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $439.92 | 2023-2025 | Imfinzi, Enhertu |
| Pfizer INC. | $426.85 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $277.06 | 2023-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $271.06 | 2023-2025 | Erleada, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $264.42 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $187.69 | 2024-2025 | |
| Lilly USA, LLC | $171.14 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Genentech USA, INC. | $163.88 | 2024-2025 | Tecentriq, Alecensa, Rozlytrek |
| Takeda Pharmaceuticals U.S.A., INC. | $155.89 | 2024-2025 | Ninlaro, Iclusig, Fruzaqla |
| Genzyme Corporation | $120.51 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $106.00 | 2023-2024 | Precisetumor, Myrisk |
| Celgene Corporation | $99.83 | 2024-2025 | Reblozyl |
| Eisai INC. | $93.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $83.36 | 2023-2025 | Ojjaara, Jemperli, Zejula |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $74.42 | 2025 | Cabometyx |
| Beigene USA, INC. | $71.47 | 2023-2024 | Brukinsa |
| Incyte Corporation | $69.60 | 2023-2024 | Jakafi |
| Tersera Therapeutics LLC | $67.74 | 2024-2025 | Zoladex |
| Array Biopharma INC | $62.14 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Blueprint Medicines Corporation | $48.41 | 2023-2024 | Ayvakit |
| Daiichi Sankyo INC. | $47.57 | 2024-2025 | Datroway, Vanflyta |
| Stemline Therapeutics INC. | $42.65 | 2025 | Orserdu |
| Springworks Therapeutics, INC. | $39.41 | 2024-2025 | Ogsiveo |
| Accord Healthcare, INC. | $38.99 | 2024-2025 | |
| Seagen INC. | $34.04 | 2023 | Adcetris, Tukysa |
| Polynovo North America LLC | $33.15 | 2025 | Novosorb Btm |
| Gilead Sciences, INC. | $31.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.56 | 2024 | Gilotrif |
| Dendreon Pharmaceuticals LLC | $29.58 | 2024 | Provenge |
| Deciphera Pharmaceuticals INC. | $28.41 | 2025 | Tgct, Qinlock |
| Emd Serono, INC. | $28.28 | 2024 | |
| Agios Pharmaceuticals, INC. | $24.88 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $22.72 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $22.58 | 2025 | |
| Pharmaand Gmbh | $21.24 | 2025 | Rubraca |
| Amgen INC. | $20.87 | 2023 | Nplate, Vectibix, Xgeva |
| Fennec Pharmaceuticals, INC. | $19.46 | 2024 | Pedmark |
| Puma Biotechnology, INC. | $19.17 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.40 | 2024 | Somatuline Depot, Onivyde |
| Coherus Oncology, INC. | $18.02 | 2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $17.36 | 2024 | Monoferric |
| Janssen Pharmaceuticals, INC | $17.07 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $16.10 | 2023 | Libtayo |
| Azurity Pharmaceuticals, INC. | $15.27 | 2025 | Vivimusta, Danziten |
| Phathom Pharmaceuticals, INC. | $13.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Kodali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.